nach oben

PharmacoEconomics

Erschienen in:

01.01.2005 | Original Research Article

Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder

verfasst von: Kristina Secnik, Andrine Swensen, Maureen J. Lage

Erschienen in: PharmacoEconomics | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Introduction: The purpose of this retrospective study was to examine the prevalence of comorbidities, resource use, direct medical costs, and the costs associated with missed work for adults diagnosed with attention-deficit hyperactivity disorder (ADHD).

Study design: From a large claims database that captures inpatient, outpatient and prescription drug services, individuals diagnosed with ADHD between the years 1999 and 2001 were retrospectively identified. The ADHD cohort (n = 2252) were matched with a non-ADHD cohort (n = 2252) on a 1: 1 ratio, based upon age, gender, metropolitan statistical area and type of insurance coverage. The ADHD cohort was compared with the non-ADHD cohort for differences in comorbidities and direct medical costs (inpatient, outpatient and prescription drug costs) using year 2001 prices.

Using data from six Fortune 200 employers, time missed from work and costs associated with absenteeism, short-term disability and worker’s compensation was examined for a subsample (n = 354) of the employees diagnosed with ADHD.

Chi-square and t-statistics were used to compare the ADHD population with the control group with regards to comorbidites and service use. Analysis of covariance and multivariate regressions were used to examine differences in days missed from work, direct medical costs and costs associated with missed work.

Results: Adults diagnosed with ADHD were significantly more likely to have a comorbid diagnosis of asthma (p = 0.0014), anxiety (p < 0.0001), bipolar disorder (p < 0.0001), depression (p < 0.0001), drug or alcohol abuse (p < 0.0001), antisocial disorder (p = 0.0081) or oppositional disorder (p = 0.0022) compared with the control group. Controlling for the impact of comorbidities, adults diagnosed with ADHD had significantly higher outpatient costs ($US3009 vs $US1492; p < 0.0001), inpatient costs ($US1259 vs $US514; p < 0.0001), prescription drug costs ($US1673 vs $US1008; p < 0.0001), and total medical costs ($US5651 vs $US2771; p < 0.0001) compared with the non-ADHD cohort. Employees diagnosed with ADHD missed significantly more days due to ‘unofficial’ absences (4.33 days vs 1.13 days; p < 0.0001).

Conclusions: The results demonstrate that adults diagnosed with ADHD have a higher prevalence of comorbidities, higher medical costs and more absences than matched individuals without ADHD. These findings suggest that there may be an opportunity for the effective treatment of ADHD to lead to cost-offsets.

American Psychiatric Association, Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

Hill JC, Schoener EP. Age-dependent decline in attention deficit hyperactivity disorder. Am J Psychiatry 1997 Sep; 154 (9): 1323–5

Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. Ann N Y Acad Sci 2001; 931: 1–16CrossRef

Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001 Jan 3; 285 (1): 60–6CrossRef

Zeitlin H. Continuities of childhood disorders into adulthood. In: Reder P, McClure M, Jolley A, editors. Family matters: interfaces between child and adult mental health. London: Routledge, 2000

Curran S, Fitzgerald M. Attention deficit hyperactivity disorder in the prison population. Am J Psychiatry 1999; 156 (10): 1664–5CrossRef

Muslow MIL O’Neal KK, Murry VM. Adult attention deficit hyperactivity disorder, the family, and child maltreatment. Trauma Violence Abuse 2001; 2 (1): 36–50CrossRef

Seidman LJ, Biederman J, Weber W, et al. Neuropsychological function in adults with attention deficit hyperactivity disorder. Biol Psychiatry 1998; 44 (4): 260–8CrossRef

Selke JH. Adults with ADHD in the workplace: a descriptive analysis and evaluation of the workplace and job satisfaction [dissertation]. Berkeley (CA): University of California, 2000

10.

Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996; 37 (6: 393–401CrossRef

11.

Biederman J, Faraone SV, Lapey K. Comorbidity of diagnosis in attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 1992; 2: 335–61CrossRef

12.

Biederman J, Famone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150 (12): 1792–8CrossRef

13.

Tannock R, Ickowicz A, Schachar R. Differential effects of methylphenidate on working memory in ADH/HD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1995; 34: 886–95CrossRef

14.

Weiss M, Hechtman LT, Weiss G. ADHD in adulthood: a guide to current theory, diagnosis and treatment. Baltimore (MD): John Hopkins University Press, 1999

15.

Biederman J, Wilens TE, Mick EA, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and comorbidity. Am J Psychiatry 1995; 152: 1652–8CrossRef

16.

Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999; 104 (2): E20CrossRef

17.

US Census Bureau. Metropolitan and micropolitan statistical area definitions [online]. Available from URL: http://www.census.gov/population/www/estimates/metrodef.html [Accessed 2004 Oct 6]

18.

Marks DJ, Newcorn JH, Halperin JM. Comorbidity in adults with attention-deficit/hyperactivity disorder. Ann N Y Acad Sci 2001; 931: 216–38CrossRef

19.

Barr WB. Schizophrenia and attention deficit disorder: two complex disorders of attention. Ann N Y Acad Sci 2001; 931: 239–50CrossRef

20.

Alpert JE, Maddocks A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996; 62 (3): 213–9CrossRef

21.

Biederman J, Faraone SV, Mick E, et al. Attention deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry 1996; 35 (8): 997–1007CrossRef

22.

Bellak L. The schizophrenic syndrome and attention deficit disorder: thesis, antithesis, and synthesis? Am Psychol 1994; 49 (1): 25–9CrossRef

23.

Raley JJ, Greenberg MS, Bemporad JR, et al. Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol 1992; 2: 267–75CrossRef

24.

Shekim W, Asarnow RE Hess E, et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 1990; 31 (5): 533–44CrossRef

25.

Barkley RA, Murphy KR, Dupaul GI, et al. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc 2002; 8 (5): 655–72CrossRef

26.

Leibson CL, Katusic SK, Barberesi WJ, et al. Use and costs of medical care for children and adolescents with and without attention deficit / hyperactivity disorder. JAMA 2001; 285 (1): 60–6CrossRef

27.

Biederman J, Milberger S, Famone SV, et al. Associations between childhood asthma and ADHD: issues of psychiatric comorbidity and familiality. J Am Acad Child Adolesc Psychiatry 1994; 33 (6: 842–8CrossRef

28.

Biederman J, Faraone SV, Spencer T, et al. Gender differences in a sample of adults with attention deficit hyperactivity disorder. Psychiatry Res 1994 Jul; 53 (1): 13–29CrossRef

29.

Osterberg E, Blomquist L, Krakau I, et al. A population study on irritable bowel syndrome and mental health. J Gastroenterol 2000 Mar; 35 (3): 264–8

30.

Trikas P, Vlachonikolis I, Fragkiadukis N. Core mental state in irritable bowel syndrome. Psychosom Med 1999 Nov-Dec; 61 (6): 781–8CrossRef

31.

Ramsey S, Summers KH, Leong SA, et al. Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002; 25 (1): 23–9CrossRef

32.

Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999; 16 (1): 1–8CrossRef

33.

Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med. 2003; 45: 5–14CrossRef

34.

SAS User’s Guide. SAS/STAT User’s Guide: version 8. Cary (NC): SAS Institute, 1999

35.

Duan, N. Smearing estimate: a nonparametric retransformation method. J Am Statist Assoc (JASA) 1983; 78 (383): 605–10CrossRef

36.

American Academy of Pediatrics. Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108 (4): 1033–44CrossRef

37.

Famone SV, Biederman J, Spencer T, et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 2000; 48 (1): 9–20CrossRef

38.

Carr RE. Panic disorder and asthma. J Asthma 1999; 36 (2): 143–52CrossRef

39.

Barkley RA. Accidents and attention-deficit/hyperactivity disorder. Trends in Evidence-Based Neuropsychiatry (TEN) 2001; 3 (4): 64–8

40.

Friedman SR. Emotion recognition, social skills and adult attention-deficit/hyperactivity disorder [dissertation]. Detroit (MI): Wayne State University, 2001

41.

Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: National estimates from the Medical Expenditure Panel Survey. Arch Pediatr Adolesc Med 2002; 156 (5): 504–11CrossRef

Titel: Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder
verfasst von: Kristina Secnik
Andrine Swensen
Maureen J. Lage
Publikationsdatum: 01.01.2005
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 1/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523010-00008

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2005

Pharmacoeconomic impact of non-compliance with statins

Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer

A review of the costs of managing childhood epilepsy

Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus

Measuring productivity changes in economic evaluation

Role of pharmacoeconomic analysis in R&D decision making